SecBot SecBot
PRESS-RELEASE ·Filed May 5, 2026

OCUL

Ocular Therapeutix, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The EPS beat and positive SOL-1 data provide near-term bullish momentum, but the revenue miss and widening losses are concerning. Watch for AXPAXLI NDA submission updates and SOL-R data in Q1 2027; the June Investor Day could be a catalyst for regulatory clarity.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.71
T+0 close · May 5, 2026 · via day close
Latest settled
−12.77%
T+60 · $8.47
Vs SPY
−15.51%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $9.71entry
  2. T+1 · 7mo ago 0.00%α −1.38% · $9.71
  3. T+5 · 6mo ago −4.43%α −6.41% · $9.28
  4. T+20 · 6mo ago −14.42%α −19.37% · $8.31
  5. T+60 · 4mo ago −12.77%α −15.51% · $8.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of -$0.32 by 9.4%, while revenue of $10.8M was below the $12.7M estimate. The beat was driven by lower-than-expected operating expenses, but the net loss widened to -$88.6M from -$64.1M YoY due to increased R&D spending on AXPAXLI trials. The stock will move on the EPS beat and positive SOL-1 data momentum, offset by revenue miss and cash burn concerns.

Key Financial Metrics

EPS
−$0.29
est −$0.32 · +9.4%
Revenue
$10.8M
est $12.7M · -15.1% · +0.8% YoY
Rating
beat

Key Facts

  • EPS of -$0.29 beat consensus of -$0.32 by 9.4%
  • Revenue of $10.8M missed consensus of $12.7M by 15%
  • Net loss widened to -$88.6M from -$64.1M YoY
  • Cash balance $666.7M, expected runway into 2028
  • AXPAXLI NDA submission for wet AMD on track, subject to FDA discussions
  • SOL-R Phase 3 topline data expected Q1 2027
  • Investor Day scheduled for June 17, 2026

Financial Impact

EPS beat of $0.03 vs consensus, revenue miss of $1.9M, net loss increase of $24.5M YoY

epsrevenuenet losscash

Risk Factors

  • Revenue miss of 15% vs consensus signals DEXTENZA growth stagnation
  • R&D spend increased 54% YoY, pressuring cash runway despite $666.7M balance
  • AXPAXLI NDA submission and FDA review timeline remain uncertain
  • SOL-R non-inferiority trial may not replicate SOL-1 superiority results

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287510

Track record

20 reports on OCUL

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
  2. Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
  3. Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
  4. Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
  6. Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
  7. Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
  8. Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
  9. Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
  10. Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 8h 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026